Advertisement

Allergic Bronchopulmonary Aspergillosis

An Evolving Challenge in Asthma
  • Brian M. Morrissey
  • Samuel Louie
Chapter
Part of the Current Clinical Practice book series (CCP)

Abstract

  • Allergic bronchopulmonary aspergillosis (ABPA) represents an immunoglobulin E-mediated hypersensitivity to fungal antigens in patients with asthma.

  • Consider the possibility of ABPA in difficult-to-control asthma cases.

  • Reactive airway disease is commonly present in patients with ABPA.

  • ABPA is not an invasive fungal infection but may occasionally mimic invasive diseases.

  • Uncontrolled ABPA leads to progressive bronchiectasis and respiratory decline.

  • Early recognition of ABPA—before bronchiectasis becomes permanent and severe—may alter the clinical course.

  • Chest imaging can assist in early diagnosis.

  • Computed tomography (CT) imaging can define the extent and severity of bronchiectasis and identify ABPA complications.

  • Control of the acute and chronic inflammatory response is central to the treatment of ABPA.

  • Antifungal therapy is an important adjunct to corticosteroids and may be steroid-sparing.

Keywords

Cystic Fibrosis Invasive Pulmonary Aspergillosis Invasive Fungal Disease Eosinophilic Pneumonia Allergic Bronchopulmonary Aspergillosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aron Y, Bienvenu T, Hubert D, et al. HLA-DR polymorphism in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1999; 104(4 Pt 1): 891–892.PubMedCrossRefGoogle Scholar
  2. 2.
    Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 2000; 16: 464–471.PubMedCrossRefGoogle Scholar
  3. 3.
    Hinson KF, Moon AJ, Plummer NS. Broncho-pulmonary aspergillosis: a review and a report of eight new cases. Thorax 1952; 7: 317–333.PubMedGoogle Scholar
  4. 4.
    Wark PA, Saltos N, Simpson J, et al. Induced sputum eosinophils and neutrophils and bronchiectasis severity in allergic bronchopulmonary aspergillosis. Eur Respir J 2000; 16: 1095–1101.PubMedCrossRefGoogle Scholar
  5. 5.
    Skov M, Poulsen LK, Koch C. Increased antigen-specific Th-2 response in allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis. Pediatr Pulmonol 1999; 27: 74–79.PubMedCrossRefGoogle Scholar
  6. 6.
    Grunig G, Corry DB, Leach MW, et al. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J Exp Med 1997; 185: 1089–1099.PubMedCrossRefGoogle Scholar
  7. 7.
    Kheradmand F, Kiss A, Xu J, et al. A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease. J Immunol 2002; 169: 5904–5911.PubMedGoogle Scholar
  8. 8.
    Khan S, McClellan JS, Knutsen AP. Increased sensitivity to IL-4 in patients with allergic bronchopulmonary aspergillosis. Int Arch Allergy Immunol 2000; 123: 319–326.PubMedCrossRefGoogle Scholar
  9. 9.
    Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 696–709.PubMedCrossRefGoogle Scholar
  10. 10.
    Chung Y, Kraut JR, Stone AM, Valaitis J. Disseminated aspergillosis in a patient with cystic fibrosis and allergic bronchopulmonary aspergillosis. Pediatr Pulmonol 1994; 17: 131–134.PubMedCrossRefGoogle Scholar
  11. 11.
    Bodey GP, Glann AS. Central nervous system aspergillosis following corticosteroidal therapy for allergic bronchopulmonary aspergillosis. Chest 1993; 103: 299–301.PubMedCrossRefGoogle Scholar
  12. 12.
    Reiff DB, Wells AU, Carr DH, Cole PJ, Hansell DM. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. Am J Roentgenol 1995; 165: 261–267.Google Scholar
  13. 13.
    Saraceno JL, Phelps DT, Ferro TJ, Futerfas R, Schwartz DB. Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 1997; 112: 541–548.PubMedCrossRefGoogle Scholar
  14. 14.
    Safirstein BH, D’Souza MF, Simon G, Tai EH, Pepys J. Five-year follow-up of allergic bronchopulmonary aspergillosis. Am Rev Respir Dis 1973; 108: 450–459.PubMedGoogle Scholar
  15. 15.
    Rosenberg M, Mintzer R, Aaronson DW, Patterson R. Allergic bronchopulmonary aspergillosis in three patients with normal chest x-ray films. Chest 1977; 72: 597–600.PubMedCrossRefGoogle Scholar
  16. 16.
    Kumar R, Gaur SN. Prevalence of allergic bronchopulmonary aspergillosis in patients with bronchial asthma. Asian Pac J Allergy Immunol 2000; 18: 181–185.PubMedGoogle Scholar
  17. 17.
    O’Connor TM, O’Donnell A, Hurley M, Bredin CP. Allergic bronchopulmonary aspergillosis: a rare cause of pleural effusion. Respirology 2001; 6: 361–363.PubMedCrossRefGoogle Scholar
  18. 18.
    Panchal N, Bhagat R, Pant C, Shah A. Allergic bronchopulmonary aspergillosis: the spectrum of computed tomography appearances. Respir Med 1997; 91: 213–219.PubMedCrossRefGoogle Scholar
  19. 19.
    Munro NC, Han LY, Currie DC, Strickland B, Cole PJ. Radiological evidence of progression of bronchiectasis. Respir Med 1992; 86: 397–401.PubMedCrossRefGoogle Scholar
  20. 20.
    Rosenberg M, Patterson R, Roberts M. Immunologic responses to therapy in allergic bronchopulmonary aspergillosis: serum IgE value as an indicator and predictor of disease activity. J Pediatr 1977; 91: 914–917.PubMedCrossRefGoogle Scholar
  21. 21.
    Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162(Pt 1): 1277–128.PubMedGoogle Scholar
  22. 22.
    Nepomuceno IB, Esrig S, Moss RB. Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Chest 1999; 115: 364–370.PubMedCrossRefGoogle Scholar
  23. 23.
    Patterson R, Greenberger PA, Radin RC, Roberts M. Allergic bronchopulmonary aspergillosis: staging as an aid to management. Ann Intern Med 1982; 96: 286–291.PubMedGoogle Scholar
  24. 24.
    Kumar R, Singh P, Arora R, Gaur SN. Effect of itraconazole therapy in allergic bronchopulmonary aspergillosis. Saudi Med J 2003; 24: 546–547.PubMedGoogle Scholar
  25. 25.
    Kiely JL, Spense L, Henry M, et al. Chest radiographic staging in allergic bronchopulmonary aspergillosis: relationship with immunological findings. Eur Respir J 1998; 12: 453–456.PubMedCrossRefGoogle Scholar
  26. 26.
    Mroueh S, Spock A. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Chest 1994; 105: 32–36.PubMedCrossRefGoogle Scholar
  27. 27.
    Marchand E, Verellen-Dumoulin C, Mairesse M, et al. Frequency of cystic fibrosis transmembrane conductance regulator gene mutations and 5T allele in patients with allergic bronchopulmonary aspergillosis. Chest 2001; 119: 762–767.PubMedCrossRefGoogle Scholar
  28. 28.
    Cordier J. Eosinophilic pneumonias. In M. I. A. K. Schwarz, T. E. (ed.). Intersitial lung disease, 4th ed. B C Decker, Inc., Hamilton, Ontario, 2003, pp. 657–700.Google Scholar
  29. 29.
    Seaton A, Seaton RA, Wightman AJ. Management of allergic bronchopulmonary aspergillosis without maintenance oral corticosteroids: a fifteen-year follow-up. QJM 1994; 87: 529–537.PubMedGoogle Scholar
  30. 30.
    Inhaled beclomethasone dipropionate in allergic bronchopulmonary aspergillosis. Report to the Research Committee of the British Thoracic Association. Br J Dis Chest 1979; 73: 349–356.CrossRefGoogle Scholar
  31. 31.
    Henderson AH, Pearson JE. Treatment of bronchopulmonary aspergillosis with observations on the use of natamycin. Thorax 1968; 23: 519–523.PubMedGoogle Scholar
  32. 32.
    Currie DC, Lueck C, Milburn HJ, et al. Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis. Thorax 1990; 45: 447–450.PubMedGoogle Scholar
  33. 33.
    Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342: 756–762.PubMedCrossRefGoogle Scholar
  34. 34.
    Salez F, Brichet A, Desurmont S, et al. Effects of itraconazole therapy in allergic bronchopulmonary aspergillosis. Chest 1999; 116: 1665–1668.PubMedCrossRefGoogle Scholar
  35. 35.
    Wark PA, Hensley MJ, Saltos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 2003; 111: 952–957.PubMedCrossRefGoogle Scholar
  36. 36.
    Murphy M, Bernard EM, Ishimaru T, Armstrong T. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997; 41: 696–698.PubMedGoogle Scholar
  37. 37.
    Morrissey BM, Evans SJ. Severe bronchiectasis. Clin Rev Allergy Immunol 2003; 25: 233–247.PubMedCrossRefGoogle Scholar
  38. 38.
    Sancho JM, Ribera JM, Rosell A, Munoz C, Feliu E. Unusual invasive bronchial aspergillosis in a patient with acute lymphoblastic leukemia. Haematologica 1997; 82: 701–702.PubMedGoogle Scholar
  39. 39.
    Pinson P, Van der Straeten M. Fibrotic stage of allergic bronchopulmonary candidiasis. Chest 1991; 100: 565–567.PubMedCrossRefGoogle Scholar
  40. 40.
    Saini SK, Boas SR, Jerath A, Roberts M, Greenberger PA. Allergic bronchopulmonary mycosis to Fusarium vasinfectum in a child. Ann Allergy Asthma Immunol 1998; 80: 377–380.PubMedCrossRefGoogle Scholar
  41. 41.
    Backman KS, Roberts M, Patterson R. Allergic bronchopulmonary mycosis caused by Fusarium vasinfectum. Am J Respir Crit Care Med 1995; 152(Pt 1): 1379–1381.PubMedGoogle Scholar
  42. 42.
    Miller MA, Greenberger PA, Amerian R, et al. Allergic bronchopulmonary mycosis caused by Pseudallescheria boydii. Am Rev Respir Dis 1993; 148: 810–812.PubMedGoogle Scholar
  43. 43.
    Cimon B, Carrere J, Vinatier JF, et al. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000; 19: 53–56.PubMedCrossRefGoogle Scholar
  44. 44.
    Shale DJ, Faux JA, Lane DJ. Trial of ketoconazole in non-invasive pulmonary aspergillosis. Thorax 1987; 42: 26–31.PubMedCrossRefGoogle Scholar
  45. 45.
    Fujimori Y, Tada S, Kataoka M, et al. Allergic bronchopulmonary aspergillosis effectively treated with itraconazole. Nihon Kokyuki Gakkai Zasshi 1998; 36: 781–786.PubMedGoogle Scholar
  46. 46.
    Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 1977; 86: 405–414.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2006

Authors and Affiliations

  • Brian M. Morrissey
    • 1
  • Samuel Louie
    • 1
  1. 1.Division of Pulmonary and Critical Care Medicine, Department of Medicine, School of MedicineUniversity of California at DavisDavis

Personalised recommendations